Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2012

View Archived Issues

Apogenix reports phase II APG-101 results

New orexin receptor antagonists patented by Actelion Pharmaceuticals

Phase II program on transdermal patch for schizophrenia begins

Study links ABC transporter gene polymorphisms to liver transplant outcomes

Pharmacodynamic efficacy of E-2096 described in animals and humans

Chinese researchers discover novel DPP IV inhibitors

Abbott presents new GSK-3 beta inhibitors

Sanofi reports novel Akt phosphorylation inhibitors

Spanish group synthesizes novel anti-inflammatory agents

Dainippon Sumitomo reviews events of first quarter fiscal 2012

StemCells receives California Institute for Regenerative Medicine award

GlaxoSmithKline develops novel orexin receptor antagonists

FDA advisory committee recommends ocriplasmin approval

Abbott and Enanta design new HCV NS3 protease inhibitors

Genentech reports on BREVACTA trial

SNPs affecting gene expression linked to late-onset Alzheimer's disease risk

NIH funds development of tissue chips to predict drug safety

Chugai Pharmaceutical profiles progress of second quarter 2012

Nuvo Research receives additional funding commitment for reformulated WF-10

Advinus Therapeutics and P2D Bioscience collaborate on ADHD

International collaboration yields new solution to defect regeneration in load-bearing long bones

Arena Pharmaceuticals transfers NDA rights to Eisai

Roche and Areva Med collaborate on radioimmunotherapy

Takeda resubmits alogliptin product NDAs

Basilea Pharmaceutica seeks European approval of antibiotic to treat pneumonia in hospitals

Shionogi seeks Japanese approval of combination drug for hypertension

Tokyo Institute of Technology and Astellas Pharma collaborate on neglected tropical diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...